Calidi Biotherapeutics (CLDI) Operating Expenses (2022 - 2026)
Calidi Biotherapeutics (CLDI) posted quarterly Operating Expenses of $4.5 million for Q4 2025, up 10.93% year-over-year from $4.0 million in Q4 2024, and down 11.53% quarter-over-quarter from $5.0 million in Q3 2025.
Calidi Biotherapeutics (CLDI) Operating Expenses (2022 - 2026) Analysis & Trends
Calidi Biotherapeutics' Operating Expenses history runs 4 years deep, the most recent figure standing at $4.5 million for Q4 2025.
- In Q4 2025, Operating Expenses rose 10.93% year-over-year to $4.5 million; the TTM figure through Dec 2025 stood at $20.2 million (down 7.05% YoY), while the FY2025 annual figure was $20.2 million, down 7.05% from the prior year.
- Operating Expenses for Q4 2025 stood at $4.5 million, down from $5.0 million in the prior quarter.
- The five-year high for Operating Expenses was $9.8 million in Q4 2023, with the low at $361622.0 in Q2 2022.
- The 4-year median for Operating Expenses is $5.3 million (2023), against an average of $5.2 million.
- The sharpest annual moves came in 2023 and 2024: Operating Expenses jumped 1707.69% in 2023, then tumbled 59.0% in 2024.
- Calidi Biotherapeutics' Operating Expenses stood at $4.7 million in 2022, then surged by 109.47% to $9.8 million in 2023, then sank by 59.0% to $4.0 million in 2024, then rose by 10.93% to $4.5 million in 2025.
- Business Quant data shows CLDI's Operating Expenses at $4.5 million in Q4 2025, $5.0 million in Q3 2025, and $5.7 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 2.89 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 960.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.21 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.06 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -784.57 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 427.03 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 541.02 Mn |
| 10 | Calidi Biotherapeutics | 1.88 Mn | -2.22 Mn | - | 4.15 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.15 Mn |
| Dec 31, 2025 | 4.47 Mn |
| Sep 30, 2025 | 5.05 Mn |
| Jun 30, 2025 | 5.66 Mn |
| Mar 31, 2025 | 5.06 Mn |
| Dec 31, 2024 | 4.03 Mn |
| Sep 30, 2024 | 5.23 Mn |
| Jun 30, 2024 | 5.77 Mn |
| Mar 31, 2024 | 6.75 Mn |
| Dec 31, 2023 | 9.82 Mn |
| Sep 30, 2023 | 7.22 Mn |
| Jun 30, 2023 | 6.54 Mn |
| Mar 31, 2023 | 5.41 Mn |
| Dec 31, 2022 | 4.69 Mn |
| Sep 30, 2022 | 6.99 Mn |
| Jun 30, 2022 | 361,622.00 |
| Mar 31, 2022 | 528,858.00 |